Page 78 - 《中国药房》2025年10期

[ 6 ] SZAREK M，REIJNDERS E，STEG P G，et al. Compari‐ matic review and meta-analysis of randomized controlled
son of change in lipoprotein（a） mass and molar concentra‐ trials[J]. Eur Heart J，2022，43（7）：e17-e25.
tions by alirocumab and risk of subsequent cardiovascular [18] KOSKINAS K C，HÄNER J，UEKI Y，et al. Association
events in ODYSSEY OUTCOMES[J]. Eur J Prev Cardiol， of lipoprotein（a） with changes in coronary atherosclerosis
2024，31（10）：e75-e78. in patients treated with alirocumab[J]. Circ Cardiovasc
[ 7 ] NGUYEN H，HUBERT B，ROGEN C，et al. Effect of ali‐ Imaging，2024，17（11）：e016683.
rocumab monotherapy vs. ezetimibe plus statin therapy on [19] SCHWARTZ G G，SZAREK M，BHATT D L，et al. Tran‐
LDL-C lowering in veterans with history of ASCVD[J]. siently achieved very low LDL-cholesterol levels by statin
Fed Pract，2024，41（11）：376-381. and alirocumab after acute coronary syndrome are asso-
[ 8 ] ZIOGOS E，CHELKO S P，HARB T，et al. Platelet activa‐ ciated with cardiovascular risk reduction：the ODYSSEY
tion and endothelial dysfunction biomarkers in acute coro‐ OUTCOMES trial[J]. Eur Heart J，2023，44（16）：1408-
nary syndrome：the impact of PCSK9 inhibition[J]. Eur 1417.
Heart J Cardiovasc Pharmacother，2023，9（7）：636-646. [20] AGNELLO F，MAURO M S，ROCHIRA C，et al. PCSK9
[ 9 ] 中国医师协会急诊医师分会，国家卫生健康委能力建设 inhibitors：current status and emerging frontiers in lipid
与继续教育中心急诊学专家委员会，中国医疗保健国际 control[J]. Expert Rev Cardiovasc Ther，2024，22（1/2/3）：
交流促进会急诊急救分会.急性冠脉综合征急诊快速诊 41-58.
治指南：2019[J].临床急诊杂志，2019，20（4）：253-262. [21] TRUDSØ L C，GHOUSE J，AHLBERG G，et al. Associa‐
[10] OZAKI Y，TOBE A，ONUMA Y，et al. CVIT expert con‐ tion of PCSK9 loss-of-function variants with risk of heart
sensus document on primary percutaneous coronary inter‐ failure[J]. JAMA Cardiol，2023，8（2）：159-166.
vention （PCI） for acute coronary syndromes （ACS） in [22] QUAGLIARIELLO V，BISCEGLIA I，BERRETTA M，
2024[J]. Cardiovasc Interv Ther，2024，39（4）：335-375. et al. PCSK9 inhibitors in cancer patients treated with
[11] 黄刚，徐俊波，朱煜欣.高血压患者合并颈动脉斑块是否 immune-checkpoint inhibitors to reduce cardiovascular
应该接受他汀类药物和/或抗血小板治疗？[J]. 中华高 events：new frontiers in cardioncology[J]. Cancers（Ba‐
血压杂志，2023，31（8）：705-708. sel），2023，15（5）：1397.
[12] DAMARPALLY N，SINHA T，MARICELA NUNEZ M， [23] DUTKA M，ZIMMER K，ĆWIERTNIA M，et al. The role
et al. Comparison of effectiveness of high dose statin of PCSK9 in heart failure and other cardiovascular di-
monotherapy with combination of statin and ezetimibe to seases：mechanisms of action beyond its effect on LDL
prevent cardiovascular events in patients with acute coro‐ cholesterol[J]. Heart Fail Rev，2024，29（5）：917-937.
nary syndrome：a systematic review and meta-analysis[J]. [24] SCHONCK W A M，STROES E S G，HOVINGH G K，
Cureus，2024，16（3）：e55922. et al. Long-term efficacy and tolerability of PCSK9 tar‐
[13] JUN J E，JEONG I K，AHN K J，et al. Combination of geted therapy：a review of the literature[J]. Drugs，2024，
low- or moderate-intensity statin and ezetimibe vs. high- 84（2）：165-178.
intensity statin monotherapy on primary prevention of car‐ [25] SEIJAS-AMIGO J，CORDERO A，OLMO R F，et al. Pa‐
diovascular disease and all-cause death：a propensity- tients with high cardiovascular risk as candidates to bem‐
matched nationwide cohort study[J]. Eur J Prev Cardiol， pedoic acid，after treatment with statins，ezetimibe and
2024，31（10）：1205-1213. PCSK9 inhibitors：an estimation and cost-effectiveness
[14] ZHANG Y H，ZHANG A J，WU Y，et al. Early addition of analysis[J]. J Cardiovasc Pharmacol，2023，81（1）：70-75.
evolocumab to statin treatment in patients with acute coro‐ [26] 胡群亮，田竺，张盛蕊，等 .PCSK9 抑制剂联合阿托伐他
nary syndrome and multivessel disease undergoing percu‐ 汀对颅内动脉粥样硬化性狭窄的治疗效果[J].中风与神
taneous coronary intervention[J]. Rev Cardiovasc Med， 经疾病杂志，2024，41（4）：349-354.
2023，24（9）：270. [27] SHI W H，XU Y，ZHOU L，et al. In-hospital initiation of a
[15] RÄBER L，UEKI Y，OTSUKA T，et al. Effect of ali‐ PCSK9 inhibitor in patients with acute coronary syn‐
rocumab added to high-intensity statin therapy on coro‐ drome：a systematic review and meta-analysis of rando-
nary atherosclerosis in patients with acute myocardial in‐ mized controlled trials[J]. Medicine （Baltimore），2024，
farction：the PACMAN-AMI randomized clinical trial[J]. 103（10）：e37416.
JAMA，2022，327（18）：1771-1781. [28] JI J R，WEI X Y，CHEN W S，et al. Effects of early
[16] OUYANG Z R，MA M Y，ZHANG Z W，et al. Targeted PCSK9 inhibitor application on inflammation levels and
degradation of PCSK9 in vivo by autophagy-tethering microcirculatory function after PCI in patients with NSTE-
compounds[J]. J Med Chem，2024，67（1）：433-449. ACS[J]. Am J Transl Res，2023，15（5）：3586-3596.
[17] GUEDENEY P，GIUSTINO G，SORRENTINO S，et al. （收稿日期：2024-11-13 修回日期：2025-04-16）
Efficacy and safety of alirocumab and evolocumab：a syste- （编辑：胡晓霖）

· 1220 · China Pharmacy 2025 Vol. 36 No. 10 中国药房 2025年第36卷第10期